Hofseth BioCare ASA: NEW PEER-REVIEWED CLINICAL STUDY ON PROGO® PUBLISHED IN BIOMEDICINES DEMONSTRATES GLP-1 BENEFITS AND AN INCREASE LEAN MUSCLE MASS

Hofseth BioCare ASA (“HBC”) announces the publication of a new peer-reviewed clinical study on its salmon protein hydrolysate ProGo® in the international scientific journal Biomedicines. The randomised, double-blind, active-controlled pilot study reports that 56 days of daily ProGo® supplementation improved multiple biological markers relevant to healthy ageing and metabolic health in overweight adults, while a protein-matched whey comparator did not.